ORIC · ORIC Pharmaceuticals
AI read · Good for ORIC
The AI's read
The findings give ORIC a scientific reason to keep testing rinzimetostat. The work is still preclinical and does not show that patients will benefit. Still, the possible advantages and support for a Phase 3 study make this favorable for ORIC.